Vici Health Sciences

Executive Summary

Vici Health Sciences is a US-based pharmaceutical R&D consulting and CDMO founded in 2020, headquartered in Cambridge, MA. The company provides end-to-end drug development services, including formulation development, analytical testing, clinical supply manufacturing, and regulatory strategy, with a focus on oncology and rare diseases. Vici supports small and emerging pharma companies in advancing New Chemical Entities (NCEs), 505(b)(2) NDAs, and ANDAs. Leveraging its expertise, Vici aims to accelerate the development of novel therapies by offering flexible, scalable solutions tailored to the needs of its clients. As a private company, Vici has not disclosed funding or valuation details but continues to operate in the competitive CDMO landscape. Its location in Cambridge positions it near a vibrant biotech hub, potentially facilitating collaborations and client engagements.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnerships or client project wins70% success
• Q4 2026Expansion of manufacturing capabilities or facility upgrades50% success
• Q1 2027Regulatory milestone for a client's drug (e.g., IND filing or NDA submission) supported by Vici40% success